Published in MAbs on January 01, 2011
Dual targeting strategies with bispecific antibodies. MAbs (2012) 2.13
Fast photochemical oxidation of proteins (FPOP) maps the epitope of EGFR binding to adnectin. J Am Soc Mass Spectrom (2014) 0.98
Emerging antibody combinations in oncology. MAbs (2011) 0.94
Pharmacokinetics of engineered human monomeric and dimeric CH2 domains. MAbs (2012) 0.94
A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties. J Biol Chem (2014) 0.88
Peptide aptamers: development and applications. Curr Top Med Chem (2015) 0.80
Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. MAbs (2015) 0.79
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. MAbs (2016) 0.77
The application of mathematical modelling to the design of bispecific monoclonal antibodies. MAbs (2016) 0.76
Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol (2015) 0.76
Cryptic activity within the Type III1 domain of fibronectin regulates tissue inflammation and angiogenesis. Curr Top Pept Protein Res (2016) 0.75
Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity. Antimicrob Agents Chemother (2017) 0.75
A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. Biometrika (1965) 14.16
Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 9.03
The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev (2006) 4.93
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (2009) 3.87
Development trends for therapeutic antibody fragments. Nat Biotechnol (2009) 3.51
Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell (1985) 2.75
The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol (1998) 2.65
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res (2008) 2.62
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol (2007) 2.53
'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng (1996) 2.44
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res (2006) 2.31
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell (2008) 2.21
Novel agents on the horizon for cancer therapy. CA Cancer J Clin (2009) 2.11
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res (2009) 1.78
Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol Pharmacol (2007) 1.57
Directed evolution of high-affinity antibody mimics using mRNA display. Chem Biol (2002) 1.57
Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. Bioessays (2008) 1.45
Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol Biol (2007) 1.41
Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res (2009) 1.40
Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin (2005) 1.32
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res (2007) 1.32
Bispecific human IgG by design. J Immunol Methods (2001) 1.28
Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol (2006) 1.24
Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol Cancer Ther (2009) 1.23
FN3: a new protein scaffold reaches the clinic. Drug Discov Today (2009) 1.23
Prediction of immunogenicity for therapeutic proteins: state of the art. Curr Opin Drug Discov Devel (2007) 1.22
Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Cancer Res (2008) 1.19
A revival of bispecific antibodies. Trends Biotechnol (2004) 1.11
Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res (1991) 1.09
Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev (2002) 1.07
Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer. J Oncol (2009) 1.02
Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin (2005) 1.00
Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int J Oncol (2009) 0.99
Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem (2003) 0.99
Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs (2011) 0.90
In-Cell Western analysis of Helicobacter pylori-induced phosphorylation of extracellular-signal related kinase via the transactivation of the epidermal growth factor receptor. Microbes Infect (2007) 0.87
Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors. J Immunol (2007) 0.84
Construction and production of an IgG-like tetravalent bispecific antibody for enhanced therapeutic efficacy. Methods Mol Biol (2009) 0.82
Expression and purification of a recombinant metal-binding T4 lysozyme fusion protein. J Biotechnol (1996) 0.80
Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1-29). J Chromatogr A (2004) 0.79
Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone. Curr Opin Drug Discov Devel (2006) 0.78
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
An emperor penguin population estimate: the first global, synoptic survey of a species from space. PLoS One (2012) 4.31
Avastin doesn't blind people, people blind people. Am J Ophthalmol (2012) 3.15
Structure of the protein phosphatase 2A holoenzyme. Cell (2006) 3.07
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res (2007) 2.84
Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol (2002) 2.81
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol (2007) 2.53
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res (2007) 2.52
Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med (2003) 2.18
Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res (2010) 2.13
Seroprevalence of Chikungunya virus infection on Grande Comore Island, union of the Comoros, 2005. Am J Trop Med Hyg (2007) 2.09
Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol (2002) 2.09
SELEX with modified nucleotides. Curr Opin Chem Biol (2008) 1.92
Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins. Cell (2006) 1.88
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res (2009) 1.78
Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy. Mol Cancer Res (2011) 1.76
Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res (2009) 1.72
Complex target SELEX. Acc Chem Res (2008) 1.71
Human and mouse mutations in WDR35 cause short-rib polydactyly syndromes due to abnormal ciliogenesis. Am J Hum Genet (2011) 1.66
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther (2009) 1.62
Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. Structure (2013) 1.59
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res (2005) 1.58
Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J Biol Chem (2006) 1.55
Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate (2010) 1.54
Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene (2005) 1.54
Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther (2006) 1.53
First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation (2007) 1.51
Entomologic investigations of a chikungunya virus epidemic in the Union of the Comoros, 2005. Am J Trop Med Hyg (2008) 1.48
p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop. EMBO J (2003) 1.44
Shear-dependent capping of L-selectin and P-selectin glycoprotein ligand 1 by E-selectin signals activation of high-avidity beta2-integrin on neutrophils. J Immunol (2004) 1.42
HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther (2008) 1.40
Chlorinated and polycyclic aromatic hydrocarbons in riverine and estuarine sediments from Pearl River Delta, China. Environ Pollut (2002) 1.39
Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res (2004) 1.33
Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys (2006) 1.30
Cyclooxygenase-2-deficient mice are resistant to endotoxin-induced inflammation and death. FASEB J (2003) 1.29
Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J (2012) 1.28
Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol (2006) 1.24
Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res (2010) 1.22
The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol (2008) 1.21
Myosin Va binding to neurofilaments is essential for correct myosin Va distribution and transport and neurofilament density. J Cell Biol (2002) 1.20
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res (2010) 1.20
Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis. Structure (2006) 1.18
Structural and biochemical insights into the regulation of protein phosphatase 2A by small t antigen of SV40. Nat Struct Mol Biol (2007) 1.18
Evidence-based choices of physicians: a comparative analysis of physicians participating in Internet CME and non-participants. BMC Med Educ (2010) 1.18
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer (2012) 1.18
Continuous in vitro evolution of a ribozyme that catalyzes three successive nucleotidyl addition reactions. Chem Biol (2002) 1.17
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. Bioorg Med Chem Lett (2006) 1.15
Quality indicators increase the reliability of microarray data. Genomics (2002) 1.14
Nanotoxicity of TiO(2) nanoparticles to erythrocyte in vitro. Food Chem Toxicol (2008) 1.14
IgE food sensitization in infants with eczema attending a dermatology department. J Pediatr (2007) 1.11
A simple, bead-based approach for multi-SNP molecular haplotyping. Nucleic Acids Res (2005) 1.11
Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. PLoS Genet (2013) 1.10
Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J Mol Biol (2004) 1.10
Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine (2009) 1.09
Identification of epitope-like consensus motifs using mRNA display. J Mol Recognit (2002) 1.09
Prospective randomized clinical trial comparing patient-controlled intravenous analgesia with patient-controlled epidural analgesia after lumbar spinal fusion. Spine (Phila Pa 1976) (2003) 1.08
Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study). Eur J Hum Genet (2008) 1.08
Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res (2010) 1.08
Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci U S A (2009) 1.07
Exploration of the P1 SAR of aldehyde cathepsin K inhibitors. Bioorg Med Chem Lett (2004) 1.06
Re: Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance. Retina (2013) 1.06
Vaccination coverage survey versus administrative data in the assessment of mass yellow fever immunization in internally displaced persons--Liberia, 2004. Vaccine (2005) 1.05
2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic acid (PSI-697): identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists. J Med Chem (2007) 1.05
Nucleic acid aptamers for target validation and therapeutic applications. J Biomol Tech (2005) 1.05
Regional decline of an iconic amphibian associated with elevation, land-use change, and invasive species. Conserv Biol (2011) 1.04
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res (2011) 1.04
Migration of intraocular silicone into the cerebral ventricles. Am J Ophthalmol (2005) 1.04
ADP-specific sensors enable universal assay of protein kinase activity. Chem Biol (2004) 1.04
Structure and mechanism of the phosphotyrosyl phosphatase activator. Mol Cell (2006) 1.03
Late rapid deterioration after endoscopic third ventriculostomy: additional cases and review of the literature. J Neurosurg (2006) 1.03
Randomized pilot trial of a synbiotic dietary supplement in chronic HIV-1 infection. BMC Complement Altern Med (2012) 1.02
ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. Cancer Res (2010) 1.02
A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother (2012) 1.02
IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res (2012) 1.01
Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors. Antimicrob Agents Chemother (2005) 1.01
Chemokine production during hypersensitivity pneumonitis. Eur J Immunol (2004) 1.00
Neural signals of extinction in the inhibitory microcircuit of the ventral midbrain. Nat Neurosci (2012) 1.00
Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Mol Cancer Ther (2006) 1.00
Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem (2011) 1.00
Effect of a low-allergen maternal diet on colic among breastfed infants: a randomized, controlled trial. Pediatrics (2005) 1.00
Views of biobanking research among Alaska native people: the role of community context. Prog Community Health Partnersh (2012) 0.99
Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer. Cancer Res (2009) 0.99
Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. J Med Chem (2009) 0.98
Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect (2012) 0.98
Application of enterococci antibiotic resistance patterns for contamination source identification at Huntington Beach, California. Mar Pollut Bull (2003) 0.98
Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus. Bioorg Med Chem Lett (2005) 0.98
Correlation of gut hormones with irritable bowel syndrome. Digestion (2008) 0.97
BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells. Clin Cancer Res (2009) 0.97
Novel therapeutic modalities to address nondrugable protein interaction targets. Neuropsychopharmacology (2008) 0.97
Dopamine stimulation of postnatal murine subventricular zone neurogenesis via the D3 receptor. J Neurochem (2010) 0.95
Co-expression of anti-NFkappaB RNA aptamers and siRNAs leads to maximal suppression of NFkappaB activity in mammalian cells. Nucleic Acids Res (2006) 0.95
The N-terminal peptide of PSGL-1 can mediate adhesion to trauma-activated endothelium via P-selectin in vivo. Blood (2002) 0.95
Protein conformational changes studied by diffusion NMR spectroscopy: application to helix-loop-helix calcium binding proteins. Protein Sci (2003) 0.95
Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists. Bioorg Med Chem Lett (2008) 0.94
GREB1 is a novel androgen-regulated gene required for prostate cancer growth. Prostate (2006) 0.94